Acute Coronary Syndrome (ACS) represents a spectrum of conditions, which are associated with acute myocardial ischemia. Over the past decades, significant advancements have been made in the management of ACS, resulting in improved patient outcomes. This article aims to provide a comprehensive overview of these advancements.
Improved risk stratification tools have played a pivotal role in ACS management. The GRACE and TIMI risk scores, for instance, have enabled clinicians to better predict patient outcomes, guiding treatment decisions. The use of high-sensitivity cardiac troponins has also improved the early diagnosis of ACS.
Pharmacological management of ACS has seen remarkable advancements. The introduction of novel antiplatelet agents, such as ticagrelor and prasugrel, has significantly reduced the risk of recurrent ischemic events. Moreover, the emergence of non-vitamin K oral anticoagulants has provided an alternative to traditional anticoagulants, with a comparable efficacy and better safety profile.
Interventional cardiology has revolutionized the management of ACS. Percutaneous coronary intervention (PCI) has become the standard of care for ST-segment elevation myocardial infarction (STEMI). Furthermore, the development of drug-eluting stents has reduced the risk of restenosis. Recent studies also suggest a potential role for complete revascularization in selected patients.
The importance of secondary prevention following an ACS event is now well-recognized. Comprehensive cardiac rehabilitation programs, lifestyle modifications, and adherence to guideline-directed medical therapy have all been shown to improve long-term outcomes.
The landscape of ACS management has significantly evolved over the past decades. These advancements have led to a paradigm shift in ACS management, with an emphasis on early diagnosis, risk stratification, aggressive intervention, and comprehensive post-ACS care. As healthcare professionals, it is imperative to stay updated with these advancements to provide optimal care to our patients.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation